The First Partial Response to PHI-101, a First-in-class Oral Checkpoint Kinase 2 Inhibitor, for Platinum-Resistant Recurrent Ovarian Cancer in a Phase IA Trial
Proceedings of the Biennial Meeting of Asian Society of Gynecologic Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined